Drug |
Pharmacologic Class |
Indication |
More Information |
| Dermatological Disorders | |||
| NexoBrid (anacaulase-bcdb) | Topically administered, bromelain-based biologic | Treatment for eschar removal in adults with deep partial thickness and/or full thickness thermal burns. | Severe Burn Therapy NexoBrid Gets FDA Approval |
| Diagnostic Agents | |||
| Cytalux (pafolacianine) | Fluorescent drug that binds to folate receptor-expressing cancer cells | To identify malignant and nonmalignant pulmonary lesions in adults with known or suspected lung cancer, in addition to detecting ovarian cancer lesions. | Cytalux Approval Expanded to Include Lung Cancer Detection During Surgery |
| Xenoview (xenon Xe 129 hyperpolarized) | Hyperpolarized contrast agent | For use with magnetic resonance imaging for evaluation of lung ventilation in adults and pediatric patients 12 years of age and older. | FDA Approves Xenoview for Evaluating Lung Ventilation |
| Infectious Disease | |||
| Actemra (tocilizumab) | Interleukin-6 antagonist | Treatment of COVID-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. | Actemra Drug Monograph |
| Sunlenca (lenacapavir) | HIV-1 capsid inhibitor | In combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. | Sunlenca Approved for Patients With Multidrug-Resistant HIV-1 Infection |
| Metabolic Disorders | |||
| Olpruva (sodium phenylbutyrate) | Nitrogen-binding agent | Treatment of patients with urea cycle disorders. | Olpruva Approved for Patients With Urea Cycle Disorders |
| Musculoskeletal Disorders | |||
| Tymlos (abaloparatide) | A human parathyroid hormone related peptide analog | To increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. | Tymlos Approved for Men With Osteoporosis at High Risk for Fracture |
| Neurologic Disorders | |||
| Briumvi (ublituximab-xiiy) | A glycoengineered monoclonal antibody that targets CD20 | Treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. | Briumvi Approved for Relapsing Forms of Multiple Sclerosis |
| Obstetrics and Gynecology | |||
| Brexafemme (ibrexafungerp) | Triterpenoid antifungal | For the reduction in the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal pediatric females. | Brexafemme Drug Monograph |
| Oncology | |||
| Rezlidhia (olutasidenib) | Isocitrate dehydrogenase-1 inhibitor. | For the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test. | Rezlidhia Drug Monograph |
| Tecentriq (atezolizumab) | Programmed death-ligand 1 blocking antibody | For the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma. | Tecentriq Drug Monograph |
| Krazati (adagrasib) | RAS GTPase (family) inhibitor | For the treatment of adults with KRASG12C-mutation locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least 1 prior systemic therapy. | Krazati Drug Monograph |
| Adstiladrin (nadofaragene firadenovec-vncg) | Nonreplicating adenoviral vector-based gene therapy | For the treatment of adults with high-risk, Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. | Gene Therapy Approved for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer |
| Lunsumio (mosunetuzumab-axgb) | CD20xCD3 T-cell engaging bispecific antibody | Treatment of adults with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy. | Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma |
| Ophthalmic Disorders | |||
| Iyuzeh (latanoprost ophthalmic solution) | Prostaglandin F2α analogue | For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. | Iyuzeh Approved for Patients With Open-Angle Glaucoma, Ocular Hypertension |
| Psychological Disorders | |||
| Vraylar (cariprazine) | Atypical antipsychotic | An adjunctive therapy to antidepressants for the treatment of major depressive disorder. | Vraylar Drug Monograph |
Publish Date
December 2022: Notable Drug Approvals
